How did CPHI's revenue and expenses trend in Q4 2024 compared to previous quarters?

**China Pharma Holdings Inc. (CPHI) experienced a decline in revenue and an increase in net loss in Q4 2024 compared to the previous quarter, Q3 2024**: 1. **Revenue Trend**: The total revenue for CPHI in Q4 2024 was $1.13 million. In Q3 2024, the revenue was $1.1 million, and in Q2 2024, it was $924,943. The revenue in Q1 2024 was $1.37 million. It indicates a decrease in revenue from Q3 to Q4, but an increase from Q2 to Q3. However, when compared to the previous year, there is a significant decline as the revenue in Q4 2023 was $1.86 million. |code|Ticker|Name|Date|Total Revenue YoY|Total Revenue|market_code| |---|---|---|---|---|---|---| |CPHI|CPHI.A|China Pharma Holdings|2023 Q4|-26.40581992468333|2149686|170| |CPHI|CPHI.A|China Pharma Holdings|2024 Q1|-30.120594401848706|1369839|170| |CPHI|CPHI.A|China Pharma Holdings|2024 Q2|-15.750522378951088|924943|170| |CPHI|CPHI.A|China Pharma Holdings|2024 Q3|-38.99773823775507|1100152|170| 2. **Expense Trend**: There are no available data on the expenses for CPHI in Q4 2024 compared to previous quarters. However, the company reported a net loss of $4.74 million for the year ended December 31, 2024, compared to a net loss of $3.08 million in the previous year. The revenue for the year was $4.5 million, a decrease from $7.0 million in the prior year, primarily due to increased competition and the company's products not qualifying for centralized procurement. 3. **Financial Performance**: The gross loss for the year was $2.0 million, up from a gross loss of $0.3 million in the previous year. Operating expenses totaled $2.6 million, with selling expenses decreasing to $0.53 million and general and administrative expenses increasing to $1.78 million. The company reported a working capital deficit of $1.7 million and cash and cash equivalents of $0.63 million as of December 31, 2024. 4. **Reverse Stock Split**: CPHI announced a 1-for-10 reverse stock split effective on April 15, 2025, to address the stock price and improve the financial position. This action indicates financial distress and attempts to enhance the stock's value for regulatory compliance. In conclusion, CPHI faced significant challenges in Q4 2024, with a decline in revenue and an increase in net loss compared to the previous quarter. The company's financial condition warrants close monitoring, and the reverse stock split is a clear indication of the measures being taken to address the stock price and improve financial stability.